Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SKN016
MIFTS: 68

Skin Disease

Categories: Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Skin Disease

About this section

MalaCards integrated aliases for Skin Disease:

Name: Skin Disease 39 12 15 17
Abnormality of the Skin 30 6
Skin Diseases, Genetic 45 74
Skin Diseases 56 45
Skin and Subcutaneous Tissue Disease 12
Dermatologic Disorders 74
Genodermatosis 12
Skin Disorder 15

Classifications:

MalaCards categories:
Anatomical: Skin diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:37
ICD9CM 36 702
NCIt 51 C27554 C3371
Sources

Summaries for Skin Disease

About this section
Disease Ontology : 12 An integumentary system disease that is located in skin.

MalaCards based summary : Skin Disease, also known as abnormality of the skin, is related to vesiculobullous skin disease and bullous skin disease, and has symptoms including pruritus, dry skin and enanthema. An important gene associated with Skin Disease is COL17A1 (Collagen Type XVII Alpha 1 Chain), and among its related pathways/superpathways are Developmental Biology and Keratinization. The drugs Dapsone and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include skin, skin and breast, and related phenotypes are craniofacial and integument

Sources

Related Diseases for Skin Disease

About this section

Diseases related to Skin Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 548)
# Related Disease Score Top Affiliating Genes
1 vesiculobullous skin disease 34.5 COL17A1 COL7A1 DST KRT14 LAMC2
2 bullous skin disease 34.4 COL17A1 DSG1 DSG3 DST
3 dermatitis 32.8 DSG1 FLG IL4 SPINK5
4 hidradenitis suppurativa 32.8 KRT10 KRT14 TNF
5 pemphigus 32.7 COL17A1 DSG1 DSG3 DST
6 epidermolysis bullosa 32.6 COL17A1 COL7A1 DST KRT14 LAMC2
7 neurotic excoriation 32.6 COL17A1 COL7A1 DST
8 psoriasis 32.6 CDSN MIR203A TNF
9 dermatitis, atopic 32.5 FLG IL4 LOR SPINK5 TNF
10 bullous pemphigoid 32.5 COL17A1 DSG1 DSG3 DST LAMC2
11 pemphigoid gestationis 32.5 COL17A1 DST
12 tungiasis 32.4 IL4 TNF
13 cellulitis 32.4 COL17A1 DSG1 DSG3 DST TNF
14 epidermolytic hyperkeratosis 32.3 FLG KRT1 KRT10 LOR
15 erythrokeratodermia variabilis et progressiva 1 32.3 GJB3 GJB4 LOR
16 ichthyosis 32.3 ABCA12 FLG KRT1 KRT10 LOR SPINK5
17 subcorneal pustular dermatosis 31.9 COL17A1 DSG1 DSG3 DST
18 keratosis 31.8 DSG1 FLG KRT1 KRT10
19 ichthyosis bullosa of siemens 31.8 KRT1 KRT10
20 cicatricial pemphigoid 31.8 COL17A1 DST LAMC2
21 white sponge nevus 1 31.8 KRT1 KRT10 KRT14
22 contact dermatitis 31.8 FLG IL4 TNF
23 linear iga disease 31.7 COL17A1 DST
24 allergic contact dermatitis 31.6 FLG IL4 TNF
25 ichthyosis, cyclic, with epidermolytic hyperkeratosis 31.6 KRT1 KRT10
26 epidermolysis bullosa acquisita 31.3 COL17A1 COL7A1 DST
27 lichen planopilaris 31.2 COL17A1 KRT14
28 hidradenitis 30.7 KRT10 KRT14 TNF
29 palmoplantar keratosis 30.4 DSG1 GJB3 KRT1 LOR
30 striate palmoplantar keratoderma 30.4 DSG1 KRT1 KRT10 KRT14
31 autoimmune disease 30.4 COL17A1 DSG1 IL4 TNF
32 netherton syndrome 30.4 DSG1 FLG SPINK5 TGM1
33 pemphigus vulgaris 30.4 DSG1 DSG3 DST
34 paraneoplastic pemphigus 30.2 COL17A1 DSG1 DSG3 DST
35 pemphigus foliaceus 30.2 DSG1 DSG3 DST
36 epidermolysis bullosa dystrophica 30.2 COL7A1 DST FLG
37 ichthyosis vulgaris 30.1 FLG KRT10 LOR SPINK5 TGM1
38 ichthyosis, congenital, autosomal recessive 4b 30.1 ABCA12 FLG TGM1
39 nevus comedonicus 30.1 ABCA12 FLG
40 autosomal recessive congenital ichthyosis 30.1 ABCA12 FLG GJB4 KRT10 LOR SPINK5
41 vohwinkel syndrome 29.9 LOR TGM1
42 granulomatous slack skin disease 12.3
43 vascular skin disease 12.0
44 degos 'en cocarde' erythrokeratoderma 11.7
45 keratolytic winter erythema 11.7
46 peeling skin syndrome 11.6
47 keratosis linearis with ichthyosis congenita and sclerosing keratoderma 11.4
48 incontinentia pigmenti 11.4
49 birt-hogg-dube syndrome 11.4
50 neurofibromatosis, type ii 11.1

Graphical network of the top 20 diseases related to Skin Disease:



Diseases related to Skin Disease
Sources

Symptoms & Phenotypes for Skin Disease

About this section

UMLS symptoms related to Skin Disease:


pruritus, dry skin, enanthema, exanthema, skin manifestations, nasal itching

MGI Mouse Phenotypes related to Skin Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 craniofacial MP:0005382 9.5 ABCA12 COL7A1 DSG3 IL4 KRT14 LAMC2
2 integument MP:0010771 9.4 ABCA12 COL7A1 DSG1 DSG3 GJB3 IL4
Sources

Drugs & Therapeutics for Skin Disease

About this section

Drugs for Skin Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1490)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dapsone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 80-08-0 2955
2
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
3
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1401-55-4
4
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1994-09-7, 94-09-7 2337
5
Acitretin Approved Phase 4,Phase 3,Phase 2,Not Applicable 55079-83-9, 69427-46-9 6437841
6
mometasone furoate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83919-23-7
7
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 104987-11-3 6473866 445643 439492
8
Acetylcholine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-84-3 187
9
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 657-24-9 14219 4091
10
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 64-17-5 702
11
Petrolatum Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 8009-03-8
12
Titanium dioxide Approved Phase 4,Phase 2,Not Applicable 13463-67-7
13
Adalimumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 331731-18-1 16219006
14
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 185243-69-0
15
Infliximab Approved Phase 4,Phase 3,Phase 2,Not Applicable 170277-31-3
16
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1959-05-2, 59-05-2 126941
17
Certolizumab pegol Approved Phase 4,Phase 3,Phase 2 428863-50-7
18
Ustekinumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 815610-63-0
19
Desonide Approved, Investigational Phase 4,Phase 3,Not Applicable 638-94-8 5311066
20
Esomeprazole Approved, Investigational Phase 4,Phase 1 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
21
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
22
Ciclopirox Approved, Investigational Phase 4,Phase 3 29342-05-0 2749
23
Amorolfine Approved, Investigational Phase 4,Phase 3 78613-35-1
24
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-21-8 3385
25
Chlorhexidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 55-56-1 2713 9552079
26
Phenol Approved, Experimental Phase 4,Not Applicable 108-95-2 996
27
Clindamycin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 18323-44-9 29029
28
carbamide peroxide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 124-43-6
29
Clobetasol Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 25122-46-7, 25122-41-2 5311051 32798
30
Mineral oil Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 8042-47-5
31
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 124-94-7 31307
32
Glycerol Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 56-81-5 753
33
Aminolevulinic acid Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 106-60-5 137
34
Isotretinoin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4759-48-2 5282379 5538
35
Salicylic acid Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 69-72-7 338
36
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-45-6 774
37
Fexofenadine Approved, Investigational Phase 4,Phase 2 83799-24-0 3348
38
Gabapentin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 60142-96-3 3446
39
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Not Applicable 148553-50-8 5486971
40
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 99011-02-6 57469
41
Benzoyl peroxide Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 94-36-0 7187
42
acetic acid Approved Phase 4 64-19-7 176
43
Hydroquinone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 123-31-9 785
44
Fluticasone Approved, Experimental Phase 4,Early Phase 1,Not Applicable 90566-53-3 62924
45
Pimecrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 137071-32-0 17753757 6447131
46
Azelaic acid Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 123-99-9 2266
47
Menthol Approved Phase 4,Phase 3 2216-51-5 16666
48
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-66-6 32051
49
Zinc oxide Approved Phase 4,Phase 3,Phase 2,Not Applicable 1314-13-2
50
Coal tar Approved Phase 4,Phase 3,Phase 1,Not Applicable 8007-45-2

Interventional clinical trials:

(show top 50) (show all 10231)
# Name Status NCT ID Phase Drugs
1 The Effect of Anti-bacterial Honey Dressing on the Healing of Split Thickness Skin Graft Donor Site Unknown status NCT02400372 Phase 4
2 Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome Unknown status NCT02550080 Phase 4 Dapsone
3 Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis Unknown status NCT01439425 Phase 4
4 Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects? Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
5 Comparison of Efficacy and Safety of 0.1% Tacrolimus and 0.1% Mometasone Furoate for Adult Vitiligo Unknown status NCT01333410 Phase 4 tacrolimus ointment;Mometasone furoate
6 The Use of Botulinum Toxin A in Two-Stage Tissue Expander/ Implant Breast Reconstruction Unknown status NCT01427400 Phase 4 Botulinum Toxin-A;Saline
7 Study of Efficacy of Metformin in the Treatment of Acanthosis Nigricans in Children With Obesity Unknown status NCT02438020 Phase 4 Metformin
8 Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients Unknown status NCT02495064 Phase 4 Mometasone Furoate Cream
9 RHYTHM (Formerly Escape II Myocardium) Unknown status NCT01548768 Phase 4 TNF inhibitors;DMARDs
10 Intense Pulsed Light as an Adjunctive to Bromonidine for the Treatment of Rosacea Unknown status NCT03053700 Phase 4 Bromonide 0.33% gel
11 The Difference of Microparticles in Patients With Psoriasis Vulgaris Who Received Stelara(Ustekinumab) Unknown status NCT02693470 Phase 4 Ustekinumab
12 Proton Pump Inhibitors Use in Patients With Psoriasis Unknown status NCT02624544 Phase 4 esomeprazole;desonide
13 Quality of Life of Patients With Psoriasis Treated With Methotrexate: Prospective, Randomized, Double-blind, Parallel Group Study. Unknown status NCT02248792 Phase 4 Methotrexate
14 A Study to Evaluate the Effectiveness of STELARA â„¢ (USTEKINUMAB) in the Treatment of Scalp Psoriasis Unknown status NCT01558310 Phase 4 Ustekinumab;Placebo
15 Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Psoriasis Vulgaris - CHINA201002016-2 Unknown status NCT01443338 Phase 4 Triptergium Wilfordii;Acitretin
16 Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer in Dermatophytic Onychomycosis Unknown status NCT01014637 Phase 4 Amorolfine (Antifungal);RV4104A, Ciclopiroxolamine, Cyclopirox (Keratolytic Agents/Antifungal)
17 Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After TNF Alfa Inhibitors Therapy Unknown status NCT01237262 Phase 4 Adalimumab, etanercept, infliximab
18 An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use Unknown status NCT01132235 Phase 4
19 Combining Acitretin and Efalizumab in the Therapy of Chronic Plaque Psoriasis Unknown status NCT00707070 Phase 4 efalizumab plus placebo;efalizumab plus acitretin
20 Home UVB Phototherapy for Psoriasis: Effectiveness, Quality of Life and Cost-Effectiveness Unknown status NCT00150930 Phase 4
21 Conventional Microneedling vs Microneedling With 5-FU (MMP) for Idiopathic Guttate Hypomelanosis (IGH) Repigmentation Unknown status NCT02904564 Phase 4
22 Effectiveness of Lavage With Alcohol - Chlorhexidine for Chemical Matricectomy Unknown status NCT01844141 Phase 4 70% alcohol;70% alcohol - 0.5% clorhexidine
23 Efficacy & Safety of Clindamycin and Tretinoin in Acne Unknown status NCT01111994 Phase 4 Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel
24 Efficacy and Safety of Runzao Zhiyang Capsule to Treat Chronic Eczema Unknown status NCT02601222 Phase 4 Runzao zhiyang capsule;Runzaozhiyang capsule agent simulation;Urea cream
25 Efficacy of Glycerol, Two Topical Steroids, and a Topical Immune Modulator Against Skin Irritation Unknown status NCT00779792 Phase 4 clobetasol;triamcinolone acetonide;tacrolimus;glycerol;vehicle ointment (paraffin oil/soft white paraffin)
26 Superficial Basal Cell Carcinoma Treatment With Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Methylaminolevulinate Unknown status NCT01491711 Phase 4 Methylaminolevulinate PDT in 2 sessions;Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT
27 Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea Unknown status NCT01139749 Phase 4 oral isotretinoin;salicylic acid and ciclopirox olamine
28 Efficacy and Safety of Treatment of Actinic Keratoses With Photodynamic Therapy Between MAL Cream and ALA Gel Unknown status NCT02647151 Phase 4 METHYLAMINOLEVULINATE HYDROCHLORIDE;AMINOLEVULINIC ACID HYDROCHLORIDE
29 Pregabalin for the Treatment of Uremic Pruritus Unknown status NCT01852318 Phase 4 pregabalin 75mg daily for 12 weeks;fexofenadine 60 mg daily for 12 weeks;placebo
30 Long Term Efficacy and Safety of Eryfotona AK-NMSC® in Patients With Actinic Keratosis Unknown status NCT01656226 Phase 4
31 Potential Effect of Topical Imiquimod on Atrial Ectopy in Patients With Actinic Keratosis Unknown status NCT01413763 Phase 4 Imiquimod cream 3.75%;Placebo cream
32 Efficacy of Pregabalin in the Management of Chronic Uremic Pruritus Unknown status NCT01073501 Phase 4 Pregabalin;Placebo
33 Safety and Tolerability of Acanya Gel in Combination With Atralin Gel for Acne Vulgaris Unknown status NCT01448733 Phase 4 Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning with with tretinoin 0.05% gel in the evening
34 A Study Comparing Combination Clindamycin Phosphate/Tretinoin Gel Alone Versus With Benzoyl Peroxide Foaming Cloths for Facial Acne Unknown status NCT01422785 Phase 4 clindamycin phosphate 1.2%/tretinoin 0.025% gel alone;clindamycin phosphate 1.2%/tretinoin 0.025% gel plus benzoyl peroxide 6% foaming cloths
35 Clinical Study to Evaluate the Efficacy of Topical Medications Containing Benzoyl Peroxide and Sulfur in the Regression in the Short Time (24 Hours) of Moderate Acne Vulgaris Grade II (Pimples) Unknown status NCT01260571 Phase 4 Benzoyl peroxide and sulfur
36 Efficacy of Quantum NPWT With Simultaneous Irrigation on Reduction of Wound Volume in Stage III/IV Pressure Ulcers. Unknown status NCT01734109 Phase 4
37 Clinical Trial of Hydroquinone Versus Miconazol in Melasma Unknown status NCT01661556 Phase 4 Miconazole;Hydroquinone
38 Olive Oil's Cream Effectiveness in Prevention of Pressure Ulcers in Immobilized Patients in Primary Care Unknown status NCT01595347 Phase 4 Hyper-oxigenated fatty acid
39 Effect of Fluticasone Proprionate 0.05% on Narrow Band UV-B in Active Vitiligo Unknown status NCT01246921 Phase 4 Fluticasone proprionate 0.05% cream
40 Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis) Unknown status NCT01082393 Phase 4 topical tacrolimus treatment;topical pimecrolimus treatment;local mometasone furoate treatment;cold cream
41 Azelaic Acid Versus Hydroquinone in Melasma Unknown status NCT00927771 Phase 4 azelaic acid gel;hydroquinone cream
42 Trial Comparing Calmoseptine Ointment and Desitin Diaper Rash Paste in Diaper Dermatitis in Neonates and Infants Unknown status NCT02716415 Phase 4 Calmoseptine Ointment;Destin Maximum Strength 40% Zinc
43 Study on the Effects of Oxygen-ozone Therapy on Back Pain in Subjects Aged 65 or Older Unknown status NCT01709058 Phase 4 Intramuscular/paravertebral injections of Oxygen-Ozone
44 Imiquimod 3.75% Cream in Combination With Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses Unknown status NCT01229319 Phase 4 Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm;Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm
45 Comparing Different Platelet Rich Plasma (PRP) Treatment Regimens for Management of Androgenic Alopecia Unknown status NCT02999737 Phase 4
46 Methylene Blue Intradermal Injection for Sentinel Lymph Node Biopsy for Breast Cancer Patients Unknown status NCT02982148 Phase 4
47 The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy Unknown status NCT02905916 Phase 4 PEG-rhG-CSF
48 Doxorubicin Hydrochloride Liposome Injection Combination With Cyclophosphamide vs Pirarubicin Combination With Cyclophosphamide in Patients With Locally Advanced Breast Cancer Unknown status NCT02903524 Phase 4 Doxorubicin Hydrochloride Liposome injection and cyclophosphamide;pirarubicin and cyclophosphamide
49 Selective Lymph Node Dissection Using Fluorescent Dye in Node-positive Breast Cancer Unknown status NCT02781259 Phase 4 Indocyanine green
50 Integrated Positron Emission Tomography Magnetic Resonance (PET/MR) of Breast Cancer Unknown status NCT02766530 Phase 4

Search NIH Clinical Center for Skin Disease

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Skin Disease cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Skin Disease:
JACE, cultured epidermis for skin replacement
Embryonic/Adult Cultured Cells Related to Skin Disease:
Cultured epidermis (JACE�) PMIDs: 23265935 17465819 11987545

Cochrane evidence based reviews: skin diseases

Sources

Genetic Tests for Skin Disease

About this section

Genetic tests related to Skin Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Skin 30
Sources

Anatomical Context for Skin Disease

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Skin Disease:

20
Skin

MalaCards organs/tissues related to Skin Disease:

42
Skin, Breast, Testes, Lymph Node, Bone, T Cells, Brain
Sources

Publications for Skin Disease

About this section

Articles related to Skin Disease:

(show top 50) (show all 1551)
# Title Authors Year
1
A case of alopecia as IgG4-related skin disease. ( 27846747 )
2019
2
Transglutaminase 1 Replacement Therapy Successfully Mitigates the Autosomal Recessive Congenital Ichthyosis Phenotype in Full-Thickness Skin Disease Equivalents. ( 30448383 )
2019
3
Association between schizophrenia and an autoimmune bullous skin disease-pemphigus: a population-based large-scale study. ( 28942756 )
2019
4
Severe hypercalcemia complicating granulomatous slack skin disease : An exceptional case. ( 31026372 )
2019
5
Severe skin disease in lupus associated with hemophagocytic lymphohistiocytosis: case reports and review of the literature. ( 30886995 )
2019
6
Inhibiting Sphingosine Kinase 2 Derived-sphingosine-1-phosphate Ameliorates Psoriasis-like Skin Disease via Blocking Th17 Differentiation of Naïve CD4 T Lymphocytes in Mice. ( 30834454 )
2019
7
Effect of using frozen-thawed bovine semen contaminated with lumpy skin disease virus on in vitro embryo production. ( 30892826 )
2019
8
Burden of skin disease in two remote primary healthcare centres in northern and central Australia. ( 30897665 )
2019
9
Bioengineered Skin Intended for Skin Disease Modeling. ( 30897791 )
2019
10
Improving Wikipedia Skin Disease Content. ( 30928466 )
2019
11
Psychological Therapies in Management of Psoriatic Skin Disease: A Systematic Review. ( 30937679 )
2019
12
Toxicological testing of allogeneic secretome derived from peripheral mononuclear cells (APOSEC): a novel cell-free therapeutic agent in skin disease. ( 30944367 )
2019
13
Detection of vaccine-like strains of lumpy skin disease virus in outbreaks in Russia in 2017. ( 30949814 )
2019
14
QUANTIFYING THE SEVERITY OF GIRAFFE SKIN DISEASE VIA PHOTOGRAMMETRY ANALYSIS OF CAMERA TRAP DATA. ( 31009309 )
2019
15
Effect of a clinical evidence technology on patient skin disease outcomes in primary care: a cluster-randomized controlled trial. ( 31019383 )
2019
16
A Multi Year Cross Sectional Study of US National Prescribing Patterns of First Generation Sedating Antihistamines in Older Adults with Skin Disease. ( 31021412 )
2019
17
Inpatient dermatology: a paradigm shift in the management of skin disease in the hospital. ( 31025738 )
2019
18
Using the basic reproduction number to assess the risk of transmission of lumpy skin disease virus by biting insects. ( 31038286 )
2019
19
Scientific Abstracts. Skin Disease Education Foundation's 43rd Annual Hawaii Dermatology Seminar. ( 31058911 )
2019
20
The Burden of Skin Disease on Deployed Servicemembers. ( 31067306 )
2019
21
Epithelial proliferation in inflammatory skin disease is regulated by tetratricopeptide repeat domain 7 (Ttc7) in fibroblasts and lymphocytes. ( 29775636 )
2019
22
Owner-reported flea treatment measures and skin disease in cats. ( 29788829 )
2019
23
A generic framework for spatial quantitative risk assessments of infectious diseases: Lumpy skin disease case study. ( 30102842 )
2019
24
Autoimmune skin disease among dermatology outpatients in Botswana: a retrospective review. ( 30168847 )
2019
25
Androgens in women: Androgen-mediated skin disease and patient evaluation. ( 30312644 )
2019
26
Androgens in women: Hormone-modulating therapies for skin disease. ( 30312645 )
2019
27
Letter to the Editor concerning "Serological and clinical evaluation of the Yugoslavian RM65 sheep pox strain vaccine use in cattle against lumpy skin disease" by Abutarbush and Tuppurainen (Transbound Emerg Dis; 2018: https://doi.org/10.1111/tbed.12923). ( 30315676 )
2019
28
We need to talk about Notch: Notch dysregulation as an epiphenomenon in inflammatory skin disease. ( 30417328 )
2019
29
Response to the Letter to the Editor concerning "Serological and clinical evaluation of the Yugoslavian RM65 sheep pox strain vaccine use in cattle against lumpy skin disease" by Abutarbush and Tuppurainen (Transbound Emerg Dis; 2018: https://doi.org/10.1111/tbed.12923). ( 30520269 )
2019
30
Spatial analysis of lumpy skin disease in Eurasia-Predicting areas at risk for further spread within the region. ( 30520550 )
2019
31
Urinary detection of corticosteroid in topical treatment of skin disease by 19F MRS. ( 30610404 )
2019
32
Connexin43 mutations linked to skin disease have augmented hemichannel activity. ( 30631135 )
2019
33
Three-dimensional reconstruction of skin disease using multi-view mobile images. ( 30657211 )
2019
34
Urticaria pigmentosa-like skin disease in a domestic shorthair cat. ( 30671254 )
2019
35
A simple method to estimate the number of doses to include in a bank of vaccines. The case of Lumpy Skin Disease in France. ( 30682041 )
2019
36
Experience of skin disease and relationships with healthcare providers: a qualitative study of Traveller women in Ireland. ( 30693477 )
2019
37
HIV-Related Skin Disease in the Era of Antiretroviral Therapy: Recognition and Management. ( 30806959 )
2019
38
Determination of lumpy skin disease virus in bovine meat and offal products following experimental infection. ( 30811855 )
2019
39
Skin disease in donkeys (Equus asinus): a retrospective study from four veterinary schools. ( 30828915 )
2019
40
Complete Genome Sequence of the Lumpy Skin Disease Virus Recovered from the First Outbreak in the Northern Caucasus Region of Russia in 2015. ( 30834374 )
2019
41
IgG4-Related Skin Disease Presenting as a Pseudolymphoma in a White Adolescent Girl. ( 30839348 )
2019
42
Humoral immune response to repeated lumpy skin disease virus vaccination and performance of serological tests. ( 30841894 )
2019
43
Regulatory T cells in inflammatory skin disease: from mice to humans. ( 30865268 )
2019
44
Bone morphogenetic protein-6 inhibits fibrogenesis in scleroderma offering new treatment options of fibrotic skin disease. ( 30878675 )
2019
45
Reply to the Letter to the Editor "Shining a Light on Concerns about Phototherapy to Prevent Allergic Skin Disease". ( 30889587 )
2019
46
Shining a Light on Concerns about Phototherapy to Prevent Allergic Skin Disease. ( 30889591 )
2019
47
Eosinophils Mediate Tissue Injury in the Autoimmune Skin Disease Bullous Pemphigoid. ( 29246800 )
2018
48
The Autoimmune Skin Disease Bullous Pemphigoid: The Role of Mast Cells in Autoantibody-Induced Tissue Injury. ( 29545809 )
2018
49
Factors Associated With Clinical Remission of Skin Disease in Dermatomyositis. ( 29114741 )
2018
50
Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis. ( 29858547 )
2018
Sources

Variations for Skin Disease

About this section

ClinVar genetic disease variations for Skin Disease:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 COL7A1 NM_000094.3(COL7A1): c.425A> G (p.Lys142Arg) single nucleotide variant Pathogenic rs121912856 GRCh37 Chromosome 3, 48630971: 48630971
2 COL7A1 NM_000094.3(COL7A1): c.425A> G (p.Lys142Arg) single nucleotide variant Pathogenic rs121912856 GRCh38 Chromosome 3, 48593538: 48593538
3 COL7A1 NM_000094.3(COL7A1): c.2005C> T (p.Arg669Ter) single nucleotide variant Pathogenic rs780261665 GRCh37 Chromosome 3, 48627691: 48627691
4 COL7A1 NM_000094.3(COL7A1): c.2005C> T (p.Arg669Ter) single nucleotide variant Pathogenic rs780261665 GRCh38 Chromosome 3, 48590258: 48590258
5 FLG NM_002016.1(FLG): c.544A> T (p.Lys182Ter) single nucleotide variant Pathogenic rs1218912272 GRCh38 Chromosome 1, 152314342: 152314342
6 FLG NM_002016.1(FLG): c.544A> T (p.Lys182Ter) single nucleotide variant Pathogenic rs1218912272 GRCh37 Chromosome 1, 152286818: 152286818
7 KRT1 NM_006121.3(KRT1): c.744T> A (p.Asp248Glu) single nucleotide variant Uncertain significance rs1555171425 GRCh37 Chromosome 12, 53072388: 53072388
8 KRT1 NM_006121.3(KRT1): c.744T> A (p.Asp248Glu) single nucleotide variant Uncertain significance rs1555171425 GRCh38 Chromosome 12, 52678604: 52678604
9 COL17A1 NM_000494.4(COL17A1): c.4145_4148del (p.Glu1382Alafs) deletion Pathogenic GRCh37 Chromosome 10, 105793710: 105793714
10 COL17A1 NM_000494.4(COL17A1): c.4145_4148del (p.Glu1382Alafs) deletion Pathogenic GRCh38 Chromosome 10, 104033953: 104033956
Sources

Expression for Skin Disease

About this section
Search GEO for disease gene expression data for Skin Disease.
Sources

Pathways for Skin Disease

About this section

Pathways related to Skin Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Developmental Biology 67
Show member pathways
 12.91 CDSN DSG1 DSG3 FLG KRT1 KRT10
2
Keratinization 67
Show member pathways
 11.78 CDSN DSG1 DSG3 FLG KRT1 KRT10
3
Cytoskeleton remodeling Neurofilaments 23
Show member pathways
 11.47 DST KRT1 KRT14
4
G-protein signaling_Rap2B regulation pathway 23
10.46 COL17A1 COL7A1 IL4 LAMC2 TNF
Sources

GO Terms for Skin Disease

About this section

Cellular components related to Skin Disease according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 cell junction GO:0030054 9.91 COL17A1 DSG1 DSG3 DST GJB3 GJB4
2 collagen-containing extracellular matrix GO:0062023 9.78 COL17A1 COL7A1 FLG LAMC2
3 extracellular matrix GO:0031012 9.67 COL17A1 COL7A1 LAMC2
4 cell-cell junction GO:0005911 9.67 CDSN COL17A1 DSG1 GJB3
5 basement membrane GO:0005604 9.46 COL17A1 COL7A1 DST LAMC2
6 desmosome GO:0030057 9.43 CDSN DSG1 DSG3
7 hemidesmosome GO:0030056 9.4 COL17A1 DST
8 intermediate filament GO:0005882 9.35 DST FLG KRT1 KRT10 KRT14
9 epidermal lamellar body GO:0097209 9.32 ABCA12 SPINK5
10 cornified envelope GO:0001533 9.23 CDSN DSG1 DSG3 FLG KRT1 KRT10
11 extracellular region GO:0005576 10.11 CDSN COL17A1 COL7A1 IL4 KRT1 KRT10

Biological processes related to Skin Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell adhesion GO:0007155 9.93 CDSN COL7A1 DSG1 DSG3 DST LAMC2
2 extracellular matrix organization GO:0030198 9.8 COL17A1 COL7A1 LAMC2 SPINK5 TNF
3 epidermis development GO:0008544 9.77 CDSN COL17A1 COL7A1 KRT14 LAMC2
4 peptide cross-linking GO:0018149 9.72 FLG KRT1 KRT10 LOR TGM1
5 keratinocyte differentiation GO:0030216 9.63 ABCA12 CDSN FLG KRT10 LOR TGM1
6 establishment of skin barrier GO:0061436 9.61 ABCA12 FLG KRT1
7 hemidesmosome assembly GO:0031581 9.56 COL17A1 DST KRT14 LAMC2
8 keratinization GO:0031424 9.56 ABCA12 DSG1 DSG3 KRT1 KRT10 KRT14
9 positive regulation of protein localization to cell surface GO:2000010 9.48 ABCA12 TNF
10 cornification GO:0070268 9.32 CDSN DSG1 DSG3 FLG KRT1 KRT10

Molecular functions related to Skin Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 structural molecule activity GO:0005198 9.35 DST FLG KRT1 KRT10 LOR
2 structural constituent of epidermis GO:0030280 8.92 FLG KRT1 KRT10 LOR
Sources

Sources for Skin Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....